FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section
16. Form 4 or Form 5 obligations may continue.
See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Afshar David					2. Issuer Name and Ticker or Trading Symbol American Oncology Network, Inc. [AONC]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) AMERICAN ONCO	(First)	,	ddle)		3. Date of Earliest Transaction (Month/Day/Year) 07/16/2024						V	Officer (give title below) Chief Financial Officer						
14543 GLOBAL PARKWAY, SUITE 110 (Street)			4	If Amendment, Date of Original Filed (Month/Day/Year)						6. Individ	Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person							
FORT MYERS	FL	33	913	_ F	Rule 10b5-1(c) Transaction Indication													
(City)	(State)	(Zi _l	0)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disp (D) (Instr. 3, 4 and 5)			Disposed Of	5. Amount of S Beneficially Ov Following Repo		ned Form: Dir		7. Nature of Indirect Beneficial			
				((Month/	Day/Year)	Code	v	Amount	amount (A) or (D)			Transaction(s) (Instr. 3 and 4)		' ' ' c		Ownership (Instr. 4)
Class A Common Stock			07/1	16/2024			Α		150,000 ⁽¹⁾ A		\$ 0	150,00	150,000		D ⁽¹⁾			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Trans Code (In	nstr. 8)	5. Number Derivative Securities (A) or Dis (D) (Instr. 5)	Acquired posed of	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Underlying Derivative (Instr. 3 and 4)				8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title		Amount or Number of Shares	r Transaction(s)				

Explanation of Responses:

1. 150,000 shares of Class A Common Stock granted for service as Chief Financial Officer and Chief Operating Officer of American Oncology Network, Inc. 97,500 shares will vest on a time-based vesting schedule over four years and 52,500 shares will vest based on a performance-based vesting schedule. Both vesting schedules will be accelerated upon a change in control.

Remarks:

Stephen Spivey, attorney-in-fact

07/18/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned person, David Afshar, hereby constitutes and appoints each of Erica Mallon, Stephen Spivey, Ashley Knox and Greg Imbrogno, each of them acting singly and with full power of substitution, the undersigned's true and lawful attorney-infact to:

- 1. execute for and on behalf of the undersigned Forms 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder;
- 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the "SEC") and any securities exchange or similar authority, including without limitation the filing of a Form ID or any other documents necessary or appropriate to enable the undersigned to file the Forms 3, 4 and 5 electronically with the SEC;
- 3. seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on securities transactions from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned's attorney-in-fact appointed by this Limited Power of Attorney and approves and ratifies any such release of information; and
- 4. take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request and on the behalf of the undersigned, are not assuming any of the undersigned's responsibilities to comply with, or any liability for the failure to comply with, any provision of Section 16 of the Exchange Act.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned's holdings of and transactions in securities, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

[SIGNATURE PAGE FOLLOWS]

85650989\V-1

IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of this third day of June, 2024.

Signed and acknowledged:

David Afshar

David Afshar

85650989\V-1